Vericel Corporation (VCEL)
| Market Cap | 1.81B |
| Revenue (ttm) | 276.26M |
| Net Income (ttm) | 16.52M |
| Shares Out | 50.93M |
| EPS (ttm) | 0.32 |
| PE Ratio | 111.50 |
| Forward PE | 82.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 720,826 |
| Open | 37.07 |
| Previous Close | 36.92 |
| Day's Range | 35.31 - 37.61 |
| 52-Week Range | 28.95 - 45.97 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 57.75 (+62.31%) |
| Earnings Date | May 7, 2026 |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic... [Read more]
Financial Performance
In 2025, Vericel's revenue was $276.26 million, an increase of 16.45% compared to the previous year's $237.22 million. Earnings were $16.52 million, an increase of 59.41%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price target is $57.75, which is an increase of 62.31% from the latest price.
News
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year...
Vericel Transcript: Leerink Global Healthcare Conference 2026
Strong Q4 and full-year growth were driven by MACI and burn care, with a 30% sales force expansion and the Arthro launch fueling commercial momentum. Guidance for 2026 is balanced, with continued focus on operational excellence, pipeline progress, and ex-U.S. expansion targeted for 2027.
Vericel Transcript: TD Cowen 46th Annual Health Care Conference
Advanced therapies for sports medicine and burn care drove strong 2024 results, with MACI and MACI Arthro fueling 20%+ growth and expanding market reach. New manufacturing capacity supports global expansion, while burn care and BARDA opportunities offer further upside.
Vericel Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue and profit growth were driven by strong MACI performance, margin expansion, and successful sales force expansion. 2026 guidance projects continued double-digit growth, with new clinical initiatives and international expansion on track.
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Q...
Vericel Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong revenue and profit growth driven by MACI's market leadership and expansion, with new FDA approvals and a larger sales force supporting continued momentum. Burn care portfolio growth and new clinical studies position the company for further market expansion and operational excellence.
Vericel Announces Preliminary 2025 Financial Results and Business Updates
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ve...
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com...
Vericel Transcript: Stephens Annual Investment Conference
Record Q3 results featured strong revenue, margin expansion, and robust cash generation. MACI growth is driven by increased surgeon training, Salesforce expansion, and new delivery methods, with international expansion planned for 2027. Burn care and NexoBrid show steady progress, while disciplined capital allocation supports long-term growth.
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com...
Vericel Earnings Call Transcript: Q3 2025
Record Q3 revenue and profit driven by strong MACI and burn care growth, with MACI Arthro adoption accelerating surgeon engagement and implant volumes. Guidance for 2025 and beyond remains robust, supported by ongoing investments and new clinical initiatives.
Vericel Reports Third Quarter 2025 Financial Results
Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of...
Vericel Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Advanced cell therapies and biologics are driving strong growth, with MACI Arthro expanding market reach and new sales force hires supporting future demand. Burn care products are building critical mass, and international and pipeline expansion are planned for the coming years.
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com...
Vericel Earnings Call Transcript: Q2 2025
Q2 saw 20% revenue growth, record gross margin, and adjusted EBITDA up 112% year-over-year. MACI and Burn Care segments both delivered strong results, with MACI Arthro driving new surgeon adoption and Epicel biopsies up nearly 40%. Full-year guidance for MACI is maintained, while Burn Care guidance is reset to reflect recent run rates.
Vericel Reports Second Quarter 2025 Financial Results
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million,...
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com...
Vericel Transcript: 2025 Truist Securities MedTech Conference
Advanced therapies for sports medicine and burn care are driving strong revenue and margin growth, with MACI and Epicel leading their markets. MACI Arthro’s rapid adoption and expanded surgeon training are expected to accelerate growth, while capital investments position the company for increased cash generation and business development.
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com...
Vericel Transcript: BofA Securities 2025 Healthcare Conference
A unique portfolio in sports medicine and burn care, including MACI and NexoBrid, drives strong revenue and profit growth, with new product launches and market expansion fueling a 20%-23% growth outlook for 2024. Over 400 surgeons trained on MACI Arthro, and burn care adoption is accelerating.
Vericel Earnings Call Transcript: Q1 2025
Record Q1 revenue driven by MACI and NexoBrid growth, with Epicel rebounding in Q2. Full-year revenue and profitability guidance raised, supported by strong MACI Arthro adoption and upcoming Salesforce expansion.
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for...
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Comp...